Biggest News Aggregation in the World
📰 Mployee Wellness Programs News

Page 22 - Mployee Wellness Programs News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Mployee Wellness Programs. Real-time updates on events, politics, business and more.

Turquoise Health Raises $30M for its Price Transparency Software

Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations.
Chris Severn Tom Bremner Andreessen Horowitz Turquoise Health San Diego Based Adams Street Partners

The Weight Loss Market in 2024: 3 Key Questions We Can No Longer Ignore

In 2024, the weight loss market finds itself at a crossroads, grappling with pivotal questions that will shape the future. The winners will prioritize affordable lifelong care, scalable coaching and support, and a diverse set of solutions that give people second and third chances along their weight loss journeys.
Weight Loss Medical Devices Healthcare Innovation Medcity News Medcity News San Francisco

Sanofi Commits $1.7B to Buy an Entire Company, But Wants Just a Single Drug

Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
United States Chiesi Farmaceutici Phouman Ashrafian Mark Lappe European Medicines Agency California Based Inhibrx

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema. If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals.
United States Mani Foroohar Kenneth Newman Kalvista Pharmaceuticals Pharming Group Ruconest Ionis Pharmaceuticals

Amgen Osteoporosis Drug Prolia Is Hit With FDA's Strictest Warning

The FDA said Amgen’s Prolia may lead to low levels of calcium, or hypocalcemia. The osteoporosis drug’s black box warning follows an FDA review of Centers for Medicare & Medicaid Services studies that found Prolia led to a significant increase in the risk of severe hypocalcemia compared to treatment with an older class of medicines.
Bio Zynteglo Eli Lilly Forteo Radius Health Centers For Medicare Medicaid Services European Commission Vertex Pharmaceuticals

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science